Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dimetotiazine is a small molecule drug belonging to the phenothiazine class, primarily used as an antimigraine agent and for its antiemetic and antihistamine properties. It acts as a serotonin receptor antagonist and histamine H1 receptor antagonist, blocking the effects of endogenous serotonin and histamine. This mechanism underlies its effectiveness in treating migraine, allergic skin conditions, nausea, vomiting (including that associated with chemotherapy), and other symptoms related to excessive serotonergic or histaminergic activity. Dimetotiazine has been marketed in Japan and Europe under brand names such as Fonazine and Migristene for the treatment of migraine disorders[3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dimetotiazine.